FDA approves dual endothelin A and B receptor antagonist for uncontrolled hypertension


The FDA approved aprocitentan, a dual endothelin A and B receptor antagonist, for the treatment of high blood pressure (BP) not adequately controlled in combination with other antihypertensive drugs.

This decision was based on the results from the phase 3 PRECISION trial, in which aprocitentan was evaluated as an add-on therapy in patients with resistant hypertension. In the PRECISION trial, treatment with aprocitentan was superior to placebo in lowering BP at week 4, and the BP-lowering effect was sustained at week 40.

The approval marks the occurrence of the first oral antihypertensive therapy that targets a new mechanism in almost 40 years. Aprocitentan targets the endothelin (ET) pathway by inhibiting the binding of ET-1 to the ETA and ETB receptors. ET-1 plays a key role in the pathophysiology of hypertension, and is a major driver of aldosterone production.

Source: Press release Idorsia, March 20, 2024

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free